Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
20.74EUR
892.24 MEUR
2.11 BEUR
43.59 M
About United Therapeutics Corporation
Sector
CEO
Martine A. Rothblatt
Headquarters
Silver Spring
Website
Employees (FY)
1.17 K
Founded
1996
FIGI
BBG000BJF7G6
United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.
An aggregate view of professional's ratings.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Curated watchlists where UTH is featured.
Frequently Asked Questions
The current price of UTH is 298.30 EUR — it has increased by 0.61% in the past 24 hours. Watch UNITED THERAPEUTICS CORP stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange UNITED THERAPEUTICS CORP stocks are traded under the ticker UTH.
UTH stock has risen by 7.73% compared to the previous week, the month change is a 16.57% rise, over the last year UNITED THERAPEUTICS CORP has showed a 45.02% increase.
We've gathered analysts' opinions on UNITED THERAPEUTICS CORP future price: according to them, UTH price has a max estimate of 372.39 EUR and a min estimate of 204.82 EUR. Watch UTH chart and read a more detailed UNITED THERAPEUTICS CORP stock forecast: see what analysts think of UNITED THERAPEUTICS CORP and suggest that you do with its stocks.
UTH stock is 1.55% volatile and has beta coefficient of 0.49. Track UNITED THERAPEUTICS CORP stock price on the chart and check out the list of the most volatile stocks — is UNITED THERAPEUTICS CORP there?
Today UNITED THERAPEUTICS CORP has the market capitalization of 13.21 B, it has increased by 7.82% over the last week.
Yes, you can track UNITED THERAPEUTICS CORP financials in yearly and quarterly reports right on TradingView.
UNITED THERAPEUTICS CORP is going to release the next earnings report on Jul 31, 2024. Keep track of upcoming events with our Earnings Calendar.
UTH earnings for the last quarter are 5.72 EUR per share, whereas the estimation was 5.29 EUR resulting in a 8.13% surprise. The estimated earnings for the next quarter are 5.90 EUR per share. See more details about UNITED THERAPEUTICS CORP earnings.
UNITED THERAPEUTICS CORP revenue for the last quarter amounts to 628.08 M EUR, despite the estimated figure of 574.90 M EUR. In the next quarter, revenue is expected to reach 632.04 M EUR.
UTH net income for the last quarter is 284.15 M EUR, while the quarter before that showed 196.69 M EUR of net income which accounts for 44.46% change. Track more UNITED THERAPEUTICS CORP financial stats to get the full picture.
No, UTH doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jun 26, 2024, the company has 1.17 K employees. See our rating of the largest employees — is UNITED THERAPEUTICS CORP on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. UNITED THERAPEUTICS CORP EBITDA is 1.22 B EUR, and current EBITDA margin is 53.35%. See more stats in UNITED THERAPEUTICS CORP financial statements.
Like other stocks, UTH shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade UNITED THERAPEUTICS CORP stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So UNITED THERAPEUTICS CORP technincal analysis shows the buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating UNITED THERAPEUTICS CORP stock shows the strong buy signal. See more of UNITED THERAPEUTICS CORP technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.